<unk>  was originally approved to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children. It is approved by the US Food and Drug Administration (FDA) for B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease greater than or equal to 0.1% as well as relapsed or refractory B-cell precursor ALL.
Blinatumomab
Loncastuximab tesirine
Margetuximab
Tositumomab
Siltuximab
Dinutuximab
Isatuximab
Polatuzumab vedotin